Evidence map›Paper›PMID 34851822›Full record

ArticleeLife2021

Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2.

Taylor P Enrico, Wayne Stallaert, Elizaveta T Wick, Peter Ngoi, Xianxi Wang, Seth M Rubin, Nicholas G Brown, Jeremy E Purvis, Michael J Emanuele

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Structural mechanism for the recognition of E2F1 by the ubiquitin ligase adaptor Cyclin F.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. HemaSphere · 2023
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Taylor P EnricoDepartment of Pharmacology. The University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID 0000-0002-5453-2868
Wayne StallaertDepartment of Genetics. The University of North Carolina at Chapel Hill, Chapel Hill, United States.
Elizaveta T WickDepartment of Pharmacology. The University of North Carolina at Chapel Hill, Chapel Hill, United States.
Peter NgoiDepartment of Chemistry and Biochemistry. University of California at Santa Cruz, Santa Cruz, United States.
Xianxi WangLineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill, Chapel Hill, United States.
Seth M RubinDepartment of Chemistry and Biochemistry. University of California at Santa Cruz, Santa Cruz, United States.ORCID 0000-0002-1670-4147
Nicholas G BrownDepartment of Pharmacology. The University of North Carolina at Chapel Hill, Chapel Hill, United States.
Jeremy E PurvisLineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID 0000-0002-6963-0524
Michael J EmanueleDepartment of Pharmacology. The University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID 0000-0003-4104-7449
University of North Carolina at Chapel Hill · USUniversity of California, Santa Cruz · US

Funding

PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIST32GM007040 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS, ROBERT A · 1985 to 2019
$6.0M
Spindle Assembly Checkpoint SilencingR35GM128855 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nicholas Gene Brown · 2018 to 2026
$4.1M
Mechanisms of Metabolic Gene Mutations in CancerR01CA163834 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY · 2012 to 2023
$3.1M
UG Support Administrative Supplement: Computational Models of the Human Cell Cycle to Reveal Disease Mechanism and Inform TreatmentR01GM138834 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeremy Purvis · 2020 to 2026
$2.7M
Controlling Stem Cell Fate through Computational ModelingDP2HD091800 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PURVIS, JEREMY · 2016 to 2018
$2.3M
SCF Ubiquitin Ligases in Cell Cycle Control and Chromosome StabilityR01GM120309 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · 2016 to 2023
$2.3M
Deubiquitinases in Cell Cycle ControlR01GM134231 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · 2020 to 2023
$1.6M
Structural mechanisms of FoxM1 regulationR01GM127707 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI RUBIN, SETH MICHAEL · 2019 to 2022
$1.2M
NCI NIH HHS R01 CA163834NICHD NIH HHS DP2 HD091800NIGMS NIH HHS R01 GM120309NIGMS NIH HHS R01 GM127707NIGMS NIH HHS R01 GM134231NIGMS NIH HHS R01 GM138834NIGMS NIH HHS R35 GM128855NIGMS NIH HHS T32 GM007040
6 · The paper itself

Abstract

Cell cycle gene expression programs fuel proliferation and are universally dysregulated in cancer. The retinoblastoma (RB)-family of proteins, RB1, RBL1/p107, and RBL2/p130, coordinately represses cell cycle gene expression, inhibiting proliferation, and suppressing tumorigenesis. Phosphorylation of RB-family proteins by cyclin-dependent kinases is firmly established. Like phosphorylation, ubiquitination is essential to cell cycle control, and numerous proliferative regulators, tumor suppressors, and oncoproteins are ubiquitinated. However, little is known about the role of ubiquitin signaling in controlling RB-family proteins. A systems genetics analysis of CRISPR/Cas9 screens suggested the potential regulation of the RB-network by cyclin F, a substrate recognition receptor for the SCF family of E3 ligases. We demonstrate that RBL2/p130 is a direct substrate of SCF

Indexed as

CyclinsHEK293 CellsHeLa CellsHumansMCF-7 CellsRetinoblastomaRetinoblastoma-Like Protein p130Stem Cell FactorCCNF protein, humanCyclinsKITLG protein, humanRBL2 protein, humanRetinoblastoma-Like Protein p130Stem Cell Factorcancer biologycell biologycell cyclecyclin FhumanRBL2/p130retinoblastomaSCFubiquitin

Identifiers

PMID34851822
PMCPMC8670743
OpenAlexW3158725180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.